Douglas McNeel

Summary

Affiliation: University of Wisconsin
Country: USA

Publications

  1. ncbi request reprint Effects of a monoclonal anti-alphavbeta3 integrin antibody on blood vessels - a pharmacodynamic study
    Dahua Zhang
    Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, WI 53792, USA
    Invest New Drugs 25:49-55. 2007
  2. pmc Real-time immune monitoring to guide plasmid DNA vaccination schedule targeting prostatic Acid phosphatase in patients with castration-resistant prostate cancer
    Douglas G McNeel
    Authors Affiliations University of Wisconsin Carbone Cancer Center and
    Clin Cancer Res 20:3692-704. 2014
  3. pmc The SSX family of cancer-testis antigens as target proteins for tumor therapy
    Heath A Smith
    Departments of Medicine and Oncology, University of Wisconsin Madison, Madison, WI 53705, USA
    Clin Dev Immunol 2010:150591. 2010
  4. pmc IgG responses to tissue-associated antigens as biomarkers of immunological treatment efficacy
    Heath A Smith
    Carbone Comprehensive Cancer Center, University of Wisconsin, 1111 Highland Avenue, Madison, WI 53705, USA
    J Biomed Biotechnol 2011:454861. 2011
  5. pmc Monitoring regulatory immune responses in tumor immunotherapy clinical trials
    Brian M Olson
    Department of Medicine, University of Wisconsin Carbone Cancer Center Madison, WI, USA
    Front Oncol 3:109. 2013
  6. pmc Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer
    Douglas G McNeel
    University of Wisconsin Carbone Cancer Center, Madison, 53792, USA
    Cancer Immunol Immunother 61:1137-47. 2012
  7. pmc His-tag ELISA for the detection of humoral tumor-specific immunity
    Vivian Goodell
    Center for Translational Medicine in Women s Health, University of Washington, Seattle, WA 98109 8050, USA
    BMC Immunol 9:23. 2008
  8. pmc Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer
    Douglas G McNeel
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Department of Biostatistics, University of Wisconsin, Madison, WI, USA
    J Clin Oncol 27:4047-54. 2009
  9. ncbi request reprint Pilot study of an HLA-A2 peptide vaccine using flt3 ligand as a systemic vaccine adjuvant
    Douglas G McNeel
    Department of Medicine, Section of Medical Oncology, University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin 53792, USA
    J Clin Immunol 23:62-72. 2003
  10. ncbi request reprint Prostate cancer immunotherapy
    Douglas G McNeel
    Department of Medicine, University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin 53792, USA
    Curr Opin Urol 17:175-81. 2007

Collaborators

Detail Information

Publications39

  1. ncbi request reprint Effects of a monoclonal anti-alphavbeta3 integrin antibody on blood vessels - a pharmacodynamic study
    Dahua Zhang
    Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, WI 53792, USA
    Invest New Drugs 25:49-55. 2007
    ..MEDI-522 is a second generation humanized anti-alphavbeta3 antibody designed for antiangiogenic therapy. The purpose of this study was to examine potential effects of this agent on blood vessels...
  2. pmc Real-time immune monitoring to guide plasmid DNA vaccination schedule targeting prostatic Acid phosphatase in patients with castration-resistant prostate cancer
    Douglas G McNeel
    Authors Affiliations University of Wisconsin Carbone Cancer Center and
    Clin Cancer Res 20:3692-704. 2014
    ....
  3. pmc The SSX family of cancer-testis antigens as target proteins for tumor therapy
    Heath A Smith
    Departments of Medicine and Oncology, University of Wisconsin Madison, Madison, WI 53705, USA
    Clin Dev Immunol 2010:150591. 2010
    ..The current review will describe the history and identification of this family of proteins, as well as what is known of their function, expression in normal and malignant tissues, and immunogenicity...
  4. pmc IgG responses to tissue-associated antigens as biomarkers of immunological treatment efficacy
    Heath A Smith
    Carbone Comprehensive Cancer Center, University of Wisconsin, 1111 Highland Avenue, Madison, WI 53705, USA
    J Biomed Biotechnol 2011:454861. 2011
    ..While the number of clinical responders was low in the vaccine-treated populations, we demonstrate that ML-BBN can be used to develop potentially predictive models...
  5. pmc Monitoring regulatory immune responses in tumor immunotherapy clinical trials
    Brian M Olson
    Department of Medicine, University of Wisconsin Carbone Cancer Center Madison, WI, USA
    Front Oncol 3:109. 2013
    ....
  6. pmc Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer
    Douglas G McNeel
    University of Wisconsin Carbone Cancer Center, Madison, 53792, USA
    Cancer Immunol Immunother 61:1137-47. 2012
    ..The identification of delayed, prolonged favorable changes in serum PSA suggests that future studies could explore this combination in studies evaluating time to disease progression...
  7. pmc His-tag ELISA for the detection of humoral tumor-specific immunity
    Vivian Goodell
    Center for Translational Medicine in Women s Health, University of Washington, Seattle, WA 98109 8050, USA
    BMC Immunol 9:23. 2008
    ....
  8. pmc Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer
    Douglas G McNeel
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Department of Biostatistics, University of Wisconsin, Madison, WI, USA
    J Clin Oncol 27:4047-54. 2009
    ..We report here the results of a phase I/IIa trial conducted with a DNA vaccine encoding human PAP in patients with stage D0 prostate cancer...
  9. ncbi request reprint Pilot study of an HLA-A2 peptide vaccine using flt3 ligand as a systemic vaccine adjuvant
    Douglas G McNeel
    Department of Medicine, Section of Medical Oncology, University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin 53792, USA
    J Clin Immunol 23:62-72. 2003
    ....
  10. ncbi request reprint Prostate cancer immunotherapy
    Douglas G McNeel
    Department of Medicine, University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin 53792, USA
    Curr Opin Urol 17:175-81. 2007
    ..This article reviews recent published findings in the area of prostate cancer immunotherapies, focusing on both passive and active immunotherapy approaches that have entered clinical trials...
  11. ncbi request reprint Cellular immunotherapies for prostate cancer
    Douglas G McNeel
    Department of Medicine Medical Oncology, University of Wisconsin Comprehensive Cancer Center, K4 518 Clinical Science Center, 600 Highland Avenue, Madison, WI 53792, USA
    Biomed Pharmacother 61:315-22. 2007
    ..We review here two cellular immunotherapies furthest in clinical development for prostate cancer, and discuss the potential challenges to the treating oncologist with the possible advent of these new therapies...
  12. ncbi request reprint Immune-based therapies for prostate cancer
    Douglas G McNeel
    Department of Medicine, University of Wisconsin Medical School, 600 Highland Avenue, Madison, WI 53792, USA
    Immunol Lett 96:3-9. 2005
    ..The findings from current trials, and the likely combination of current immunotherapy approaches with conventional therapies, portends a hopeful future for the treatment of prostate cancer...
  13. ncbi request reprint Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion
    Douglas G McNeel
    University of Wisconsin Comprehensive Cancer Center, Madison, 53792, USA
    Clin Cancer Res 11:7851-60. 2005
    ..These findings suggest the MEDI-522 could be further investigated as an antiangiogenic agent for the treatment of cancer...
  14. pmc A phase 1/1b study of satraplatin (JM-216) in combination with docetaxel in patients with advanced solid tumors and metastatic castrate-resistant prostate cancer
    Jeremy Cetnar
    University of Wisconsin Carbone Cancer Center, Wisconsin Institutes for Medical Research, Madison, WI 53705, USA
    Urol Oncol 31:436-41. 2013
    ....
  15. ncbi request reprint A phase I study of a DNA vaccine targeting prostatic Acid phosphatase in patients with stage D0 prostate cancer
    Sarah Zlotocha
    Genitourinary Oncology Group at University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin 53792, USA
    Clin Genitourin Cancer 4:215-8. 2005
  16. ncbi request reprint Immunotherapy for prostate cancer - recent progress in clinical trials
    Ryan T Kipp
    University of Wisconson School of Medicine and Public Health, Madison, WI, USA
    Clin Adv Hematol Oncol 5:465-74, 477-9. 2007
    ..The current article reviews recent trials evaluating immune-modulating agents, antigen-specific active immunotherapy, and combination therapies in clinical development for the treatment of prostate cancer...
  17. doi request reprint Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer
    Steven Attia
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, WI 53792, USA
    Clin Cancer Res 14:2437-43. 2008
    ..Doxercalciferol (1 alpha-hydroxyvitamin D2) had modest activity in phase I/II trials. Preclinical data support combining vitamin D analogues with docetaxel to treat AIPC...
  18. ncbi request reprint Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells
    Laura E Johnson
    Department of Medicine, University of Wisconsin, Madison, WI 53792, USA
    Cancer Immunol Immunother 56:885-95. 2007
    ..Overall, DNA vaccines provide a safe and effective method of generating prostate antigen-specific T cell responses. These findings support the investigation of PAP-specific DNA vaccines in human clinical trials...
  19. ncbi request reprint GVAX: an allogeneic, whole-cell, GM-CSF-secreting cellular immunotherapy for the treatment of prostate cancer
    James E Ward
    Internal Medicine Resident University of Wisconsin, Department of Medicine, Madison, WI 53792, USA
    Expert Opin Biol Ther 7:1893-902. 2007
    ....
  20. pmc A phase I pharmacokinetic and pharmacodynamic correlative study of the antisense Bcl-2 oligonucleotide g3139, in combination with carboplatin and paclitaxel, in patients with advanced solid tumors
    Glenn Liu
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, Wisconsin 53792, USA
    Clin Cancer Res 14:2732-9. 2008
    ..The effect of G3139 treatment on Bcl-2 expression in peripheral blood mononuclear cells (PBMC) and paired tumor biopsies was also determined...
  21. doi request reprint DNA vaccines for the treatment of prostate cancer
    Sheeba Alam
    Department of Medicine, University of Wisconsin Carbone Comprehensive Cancer Center, Madison, WI, USA
    Expert Rev Vaccines 9:731-45. 2010
    ..This article focuses on DNA vaccines specifically in the context of prostate cancer treatment, focusing on antigens targeted in preclinical models, recent clinical trials and efforts to improve the potency of these vaccines...
  22. pmc DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer
    Jordan T Becker
    Department of Medicine, University of Wisconsin Carbone Comprehensive Cancer Center, Madison, WI 53705, USA
    J Immunother 33:639-47. 2010
    ..Moreover, these results suggest that DNA vaccines targeting PAP could potentially be combined in heterologous immunization strategies with other vaccines to further augment PAP-specific T-cell immunity...
  23. ncbi request reprint Prostate cancer antigens and vaccines, preclinical developments
    Douglas G McNeel
    Department of Medicine, University of Wisconsin, K4 518 Clinical Science Center, Madison, WI 53792, USA
    Cancer Chemother Biol Response Modif 22:247-61. 2005
  24. pmc HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase
    Brian M Olson
    Department of Medicine, University of Wisconsin, Madison, WI 53792, USA
    Cancer Immunol Immunother 59:943-53. 2010
    ..In addition, we propose that the epitopes identified here could be used to monitor immune responses in HLA-A2+ patients receiving vaccines targeting PAP to identify potentially therapeutic immune responses...
  25. ncbi request reprint Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP)
    Laura E Johnson
    Department of Medicine, Section of Medical Oncology, University of Wisconsin Madison, K4 518 Clinical Science Center, 600 Highland Avenue, Madison, WI 53792, USA
    Vaccine 24:293-303. 2006
    ..These findings support the further clinical evaluation of pTVG-HP in patients with prostate cancer...
  26. ncbi request reprint Newer therapies in advanced prostate cancer
    Robert B Hegeman
    Department of Medicine, University of Wisconsin Comprehensive Cancer Center, Clinical Science Center, Madison, WI 53792, USA
    Clin Prostate Cancer 3:150-6. 2004
    ..This article reviews some of the newer therapies being developed and evaluated, including the epothilone analogues, human epidermal growth factor receptor pathway inhibitors, angiogenesis inhibitors, and endothelin receptor antagonists...
  27. ncbi request reprint Humoral immune responses to testis antigens in sera from patients with prostate cancer
    Luke H Hoeppner
    Department of Medicine, University of Wisconsin, Madison, WI 53792, USA
    Cancer Immun 6:1. 2006
    ..Each was independently identified from different subjects with prostate cancer. Antigens identified by these studies can be investigated further as potential prostate cancer tumor antigens...
  28. ncbi request reprint Identification of autoantibodies elicited in a patient with prostate cancer presenting as dermatomyositis
    Colin J Mooney
    Department of Medicine, University of Wisconsin, Madison, Wisconsin 53792, USA
    Int J Urol 13:211-7. 2006
    ..We hypothesized that in this particular patient, proteins produced by the neoplastic prostatic tissue, which might be normally expressed in muscle tissue, were immunologically recognized as autoantigens...
  29. ncbi request reprint Antigen-specific IgG elicited in subjects with prostate cancer treated with flt3 ligand
    Edward J Dunphy
    Department of Medicine, Section of Medical Oncology, University of Wisconsin, Madison, Wisconsin 53792, USA
    J Immunother 28:268-75. 2005
    ..The authors suggest that MAD-CaP-5 could be explored as a novel prostate cancer antigen, and that this approach can be used to identify immunologically recognized proteins following any specific intervention...
  30. ncbi request reprint Endothelin receptor antagonists in cancer therapy
    Mihailo Lalich
    Genitourinary Oncology Research Group, University of Wisconsin, Paul P Carbone Comprehensive Cancer Center, Madison, Wisconsin, USA
    Cancer Invest 25:785-94. 2007
    ..Although this class of drugs is promising for targeted anti-cancer therapy, their role in treatment remains to be defined by completion of future clinical trials...
  31. ncbi request reprint Antibody and T-cell responses specific for the androgen receptor in patients with prostate cancer
    Brian M Olson
    Department of Oncology, University of Wisconsin Madison, Madison, Wisconsin, USA
    Prostate 67:1729-39. 2007
    ..In this report, we evaluated whether patients with prostate cancer have pre-existing immune responses specific for the AR as evidence that the AR also might be pursued as an immunological target antigen...
  32. ncbi request reprint Methods for constructing and evaluating antitumor DNA vaccines
    Brian M Olson
    Department of Medicine, Section of Medical Oncology, University of Wisconsin Madison, USA
    Methods Mol Biol 542:211-43. 2009
    ..By following these protocols, it is possible to construct, purify, deliver, and evaluate the efficacy of antitumor DNA vaccines...
  33. ncbi request reprint Inducible expression of a prostate cancer-testis antigen, SSX-2, following treatment with a DNA methylation inhibitor
    Jason A Dubovsky
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, Wisconsin, USA
    Prostate 67:1781-90. 2007
    ..We have been seeking to identify immunologically recognized proteins, cancer-testis antigens (CTA) in particular, in patients with prostate cancer that would be rational target antigens...
  34. pmc Prostate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responses
    Matthew D Morse
    Department of Cancer Biology, University of Wisconsin Carbone Comprehensive Cancer Center, Madison, WI 53705, USA
    Hum Immunol 71:496-504. 2010
    ..The optimal timing and sequence of androgen deprivation with immune-based therapies awaits future experimental evaluation...
  35. pmc An aberrant prostate antigen-specific immune response causes prostatitis in mice and is associated with chronic prostatitis in humans
    Yafei Hou
    Division of Hematology Oncology, Department of Medicine, University of California, San Francisco, California 94143, USA
    J Clin Invest 119:2031-41. 2009
    ..Moreover, SVS2 and semenogelin are among the relevant autoantigens in mice and humans, respectively...
  36. ncbi request reprint Soluble cytokines can act as effective adjuvants in plasmid DNA vaccines targeting self tumor antigens
    Mary L Disis
    Division of Oncology, University of Washington, Seattle, Washington 98195 6527, USA
    Immunobiology 207:179-86. 2003
    ..Antibodies directed against rat neu were not elicited with this approach, indicating that the neu specific T cell immune response elicited with plasmid DNA was skewed towards cell-mediated rather than humoral immunity...
  37. ncbi request reprint Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy
    David B Agus
    Cedars Sinai Prostate Cancer Center, Los Angeles, CA 90048, USA
    J Clin Oncol 25:675-81. 2007
    ..The aim of this single-arm phase II clinical study was to assess the efficacy and safety of single-agent pertuzumab in castration-resistant prostate cancer (CRPC) patients who had experienced progression after prior chemotherapy...

Research Grants8

  1. Androgen receptor targeted vaccines for prostate cancer
    Douglas G McNeel; Fiscal Year: 2010
    ..Finally, this proposal will evaluate these findings in a human clinical trial in patients at high risk for prostate cancer metastatic recurrence. ..
  2. A Phase 1 Study/DNA-Based Vaccine vs Prostatic Acid Pase
    Douglas McNeel; Fiscal Year: 2003
    ..This trial will serve as a platform and model for clinical trial evaluation of antigens identified in the second aim of the proposal. ..
  3. A Phase 1 Study/DNA-Based Vaccine vs Prostatic Acid Pase
    Douglas McNeel; Fiscal Year: 2005
    ..This trial will serve as a platform and model for clinical trial evaluation of antigens identified in the second aim of the proposal. ..
  4. A Phase 1 Study/DNA-Based Vaccine vs Prostatic Acid Pase
    Douglas McNeel; Fiscal Year: 2002
    ..This trial will serve as a platform and model for clinical trial evaluation of antigens identified in the second aim of the proposal. ..
  5. A Phase 1 Study/DNA-Based Vaccine vs Prostatic Acid Pase
    Douglas McNeel; Fiscal Year: 2004
    ..This trial will serve as a platform and model for clinical trial evaluation of antigens identified in the second aim of the proposal. ..
  6. A Phase 1 Study/DNA-Based Vaccine vs Prostatic Acid Pase
    Douglas McNeel; Fiscal Year: 2006
    ..This trial will serve as a platform and model for clinical trial evaluation of antigens identified in the second aim of the proposal. ..